Summary
This prediction ended on 21.05.22 with a price of €25.75. Massive losses of -38.00% were the result for the BUY prediction by Maxfloh. Maxfloh has 70% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Evotec SE | 9.016% | 9.016% | -18.506% |
| iShares Core DAX® | 2.112% | -0.367% | 13.466% |
| iShares Nasdaq 100 | -2.197% | -3.794% | 38.426% |
| iShares Nikkei 225® | -1.555% | -7.320% | 18.451% |
| iShares S&P 500 | -0.472% | -2.078% | 27.488% |
According to Maxfloh what are the pros and cons of Evotec SE for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Standard Investments for future growth
Innovative
Some uniques
Known brand
Future proof or reliable business model
Revenue growth >5% per year expected
Very capable Management
Cons
Comments by Maxfloh for this prediction
In the thread Evotec AG diskutieren
Buy mit Kursziel 45,0